Drug Trial Radar · NCT06669351
Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza
Last checked: Nov 20, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
98
Actual
Start
Oct 31, 2024
Primary completion
Jul 15, 2025
Study completion Jul 15, 2025
Sponsor
- Lead sponsor
- Nanjing Zenshine PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, positive controlled, phase III trial to evaluate the safety and efficacy of ZX-7101A tablets versus oseltamivir phosphate suspension in children aged ≥5 years and \< 12 years with uncomplicated influenza.
Conditions
- Respiratory Viral Infection
Interventions
ZX-7101ADrug
On day1: Take two tablets of ZX-7101A orally once (specification: 10mg/ tablet) with appropriate amount of warm water
Placebo for ZX-7101A tabletOther
Placebo for ZX-7101A tablet: The appearance and properties of placebo tablets were identical to those of the trial drug ZX-7101A tablets. On Day 1, two placebo for ZX-7101A tablets were taken orally with appropriate warm water.
Oseltamivir phosphate dry suspensionDrug
Drug: Oseltamivir phosphate dry suspension: From Day1 to Day 5 : Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label.
Placebo for Oseltamivir phosphate dry suspension:Other
Drug: Placebo for Oseltamivir phosphate dry suspension: From Day1 to Day 5 : Placebo for Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic parameters of ZX-7101A and its metabolite ZX-7101 in plasmaTime frame: Part 1: 1~2, 4, 8, 24, 96 ,192, 336 hours post-dose
- Pharmacokinetic parameters of ZX-7101A and its metabolite ZX-7101 in plasmaTime frame: Part 1: 1~2, 4, 8, 24, 96 ,192, 336 hours post-dose
- Pharmacokinetic parameters of ZX-7101A and its metabolite ZX-7101 in plasmaTime frame: Part 1: 1~2, 4, 8, 24, 96 ,192, 336 hours post-dose
- Pharmacokinetic parameters of ZX-7101A and its metabolite ZX-7101 in plasmaTime frame: Part 1: 1~2, 4, 8, 24, 96 ,192, 336 hours post-dose
- Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0Time frame: Part 2: From day1 up to day15
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Baoding Hospital of Beijing Children's Hospital, Capital Medical University
Baoding, Hebei, China
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, China
Children's Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.